Category Archives: Immunology

The outing of science – TT Newsday

Commentarymarinasb57 Minutes Ago -

When I worked as a BBC programme producer, I became deeply aware of the disconnect between science and the people. In the BBCs vast array of programmes, science and scientists seemed to be in a box of their own. They lived in ivory towers, impervious to humankind, who one might imagine were supposed to be the beneficiaries of their work and great minds.

The huge ructions that took place at that time, staged by animal-rights groups which had turned to extreme violence in protest over the use of animals in laboratory testing, started winkling scientists out and making them accountable for their work. The men in white coats resisted but could not withstand the onslaught.

The BBCs science programmes were then mainly weekly magazine formats with short, interesting exposes of scientific developments, such as Science Now or a programme on medicine or stargazing. All very interesting but safe stuff.

The protests changed that by making scientists and their work big news stories. Yet, when I tried, in my BBC capacity, to encourage scientists to take part in wide-ranging discussion programmes, they recoiled so unused were they to being in an environment where the talk was about more than science.

One scientist declined my invitation, explaining that a scientists place was in the laboratory, not holding forth in public arenas. He may not have meant that it was a time-waster mixing it up with people who were challenged to understand what he said. And I cannot imagine what he thought about me telling him that his work had no relevance if it stayed in the lab.

However, through the strategic featuring of reputable scientists with a broader view of the role of the scientist in society, we gradually made others see the merits of wider communication.

In the late 1980s, Miroslav Holub helped break the ice. A wonderfully charming man, he was a Czech immunologist whose poetry casually revealed the influence of his scientific knowledge and was as much admired as his scientific work.

He would never have imagined being as famous as Dr Fauci, the immunologist and chief medical adviser to the US President whom Donald Trump tried to discredit and instead made into a household name, but, in fact, had Holub been around now, he would have brought much to the debate and be the living proof of the benefits of an open approach to science. Because of his intellectual breadth he thought boldly about immunology, and his ideas have gained new currency, according to his fellow Czech immunologists.

People educated when I was all had to come to terms with CP Snows analysis that the western world was divided into two cultures: science and the arts. Himself a physicist, Snow critiqued the complete ignorance about scientific ideas amongst even the most highly educated who commonly regarded scientists as illiterate.

And it is true, few people who could look at a Picasso painting and be moved by it considered it relevant to be awed by the wonder of a scientific theory, when in fact art and science, although often polarised, are two elemental parts of the human experience.

The fault is that we were educated to consider art as of and for the people, and science the opposite. Science was for nerds and the arts were for those not bright enough to study it.

Alas, some of this thinking still prevails in schools in TT. A young relative in a prestige school and with a bent for science not so long ago brushed off my entreaties to read a novel, assuring me that he had no need of that.

My programme trail blazed with fruitful discussions about the two cultures divide and might include David Attenborough, whose nature films played a major role in proving that we all belong to the same wondrous world, and Ernst Gombrich, author of The Story of Art, the great classic. People who had split the atom and those who had won Nobel prizes for literature exchanged ideas on air, or the biographer Brenda Maddox who reclaimed overlooked female scientists, and perhaps David Hockney, with his extraordinarily broad view of life, would have a conversation about exclusion or about Darwin. The audience rocketed and we helped turn the tide.

Today, scientists populate all manner of mainstream broadcasting in the UK and elsewhere and are keen to listen to the views and concerns of non-scientists as much as give insights into their own work.

A 2014 UK Public Attitudes to Science Survey revealed that two-thirds of respondents had experienced a science-related leisure or cultural activity and were just as likely to attend a non-science related cultural event. Londons Science Museum attendees are just as interested in the arts as science, its 2017 survey showed. The rise of health science, space travel and the internet have helped popularize science.

The pandemic has brought it more out of the woodwork still. Holub would be amazed that the man in the street now argues about immunology and has a theory of his very own.

Original post:
The outing of science - TT Newsday

New immunotherapy treatment for cancer patients is more effective and less dangerous – News-Medical.Net

Cell toxicity during immunotherapy is a major limitation to cancer treatment, but researchers are now able to isolate harmful cell reactions with a renewed potential to offer treatment without side effects.

Immunotherapy. Image Credit: Lightspring/Shutterstock.com

Despite immunotherapy rapidly advancing the field of cancer treatment, inflammatory reactions in healthy tissues frequently trigger side effects that lead to the permanent discontinuation of treatment. Indeed, the treatment is based on massive stimulation of the immune system but does not proceed without consequences as cell populations suffer from toxic effects.

This induced toxicity remains poorly understood, but scientists from the University of Geneva (UNIGE), Switzerland, and Harvard Medical School, United States, have succeeded in establishing a breakthrough to distinguish deleterious from beneficial cells produced during the immune reaction.

"When the immune system is activated so intensively, the resulting inflammatory reaction can have harmful effects and sometimes cause significant damage to healthy tissue", stated Mikal Pittet, holder of the ISREC Foundation Chair in Onco-Immunology at UNIGE Faculty of Medicine Department of Pathology and Immunology and Centre for Translational Research in Onco-Haematology.

Therefore, we wanted to know if there are differences between a desired immune response, which aims to eliminate cancer, and an unwanted response, which can affect healthy tissue. The identification of distinctive elements between these two immune reactions would indeed allow the development of new, more effective and less toxic therapeutic approaches."

The study, published in the journal Science Immunology, showed that cell populations could be distinguished based on whether they were deleterious immune reactions or those targeting tumor cells that are sought after. Such findings may provide more accurate and more effective treatments whilst minimizing the harmful by-products incurred during immunotherapy.

Researchers used samples from liver biopsies from patients who had suffered such toxic reactions to study the cellular and molecular mechanisms causing such reactions.

During immunotherapy, macrophage and neutrophil populations appear to be the two main cell types responsible for attacking healthy tissue but are not involved in killing targeted cancer cells. Dendritic cells are also not involved in attacking healthy tissue but are essential cell types for eliminating cancer cells.

"Immunotherapies can trigger the production of specialized proteins that alert the immune system and trigger an inflammatory response, explains Mikal Pittet. In a tumor, these proteins are welcome because they allow the immune system to destroy cancerous cells. In healthy tissue, however, the presence of these same proteins can lead to the destruction of healthy cells. The fact that these inflammatory proteins are produced by such different cells in tumors and healthy tissue is, therefore, an interesting finding."

However, the cell types involved differ in density as dendritic cells are very rare whereas macrophages and neutrophils are much more common, this is a key indication as to which cells may be responsible for unwanted cell damage. Importantly, some macrophages contained within organs do not necessarily inhibit inflammation but, when stimulated by immunotherapies they trigger a harmful inflammatory response in the healthy tissue where they reside, thus explaining why toxicity can affect different organs.

The production of inflammatory proteins by macrophages when activated by drugs then activates neutrophils in turn, which execute the harmful toxic reaction. This chain of reaction is a key process to the inflammatory response and induced cell toxicity observed in immunotherapy.

Mikal Pittet suggests "This opens the possibility of limiting immunotherapy's side effects by manipulating neutrophils".

By testing this loophole in mice, the researchers were able to short-circuit this process using inhibitors that negate the action of factors produced by neutrophils. These inhibitors are already being used to modulate the immune response in people with arthritis and could perhaps be useful in inhibiting the toxic effects of neutrophils during immunotherapy.

Furthermore, inhibiting neutrophils could be a more effective way to fight cancer: in addition to triggering a toxic response, some of these cells also promote tumor growth. Thus, by managing to control them, we could have a double beneficial effect: overcome the toxicity in healthy tissues, and limit the growth of cancerous cells"

Mikal Pittet

See original here:
New immunotherapy treatment for cancer patients is more effective and less dangerous - News-Medical.Net

WellNow Allergy is launched to bring ease and flexibility to testing and immunotherapy, can follow up in Batavia – The Batavian

Press release:

BUFFALOWellNow Allergy, an affiliate of leading urgent care providerWellNow Urgent Care, is now accepting patients in Western New York to provide allergy sufferers of all ages with convenient, on-demand access to allergy testing and immunotherapy (also known as allergy shots).

Children and adults interested in seeing an allergist to diagnose and treat their environmental allergies can schedule an initial appointment with same-day allergy test with Dr. Jeanne Lomas, director of Allergy & Immunology, at WellNow AllergysClarenceorOrchard Parkcenters.

Follow-up allergy shots, if needed, can be scheduled at any of WellNow Urgent Cares 17 locations in Western New York, including one in Batavia at4189 Veterans Memorial Drive, Batavia. It is open from 8 a.m. 8 p.m. Same-day PCR* Results Testing Time: 2:20 p.m. Tests administered after this time will return results within 24 hours.

There is a critical need for easier access to allergy services in the United States, as the number of board-certified allergists currently represents only a small fraction of all practicing physicians.

In Western New York, one of the most allergic and asthmatic regions in the country, the shortage of allergy doctors and clinics has become particularly pronounced as incidences of environmental allergies and asthma continue to rise year over year.

Allergy patients in Western New York typically face an average six-week wait to see an allergy doctor with little flexibility to cancel or change appointments if needed, and to schedule immunotherapy visits at times that dont interfere with work, school and everyday life.

Allergies and asthma are on the rise, especially in the Western New York region, and unfortunately, so is the time it takes for patients to actually see an allergist, said John Radford, M.D., president at WellNow Urgent Care.

Theres a clear need for better access, convenience and ease when it comes to allergy diagnosis and treatment. Were excited to deliver a better experience to patients suffering from allergy symptoms, and were thrilled to welcome Dr. Jeanne Lomas to lead our allergy service.

Lomas attended the University at Buffalo for undergraduate studies and completed her medical degree at Lake Erie College of Osteopathic Medicine in Erie. She completed her pediatric residency, chief residency and allergy fellowship training at the University of Rochester.

Most recently, she held a dual appointment at the University of Rochester in the department of Pediatric Allergy & Immunology as well as the department of Allergy, Immunology & Rheumatology. During her time at the University of Rochester, Lomas treated both adult and pediatric patients and served as clinical director for Pediatric Allergy & Immunology and co-director of the Eosinophilic Esophagitis (EoE) program.

"A six-week wait to see an allergist is simply unacceptable, especially when proper diagnosis and treatment of allergies can make such a significant impact on a patient's quality of life," Lomas said. "That's why I'm so proud to introduce WellNow Allergy. Our patients can go online to schedule an appointment with us within three weeks.

"Even more important, perhaps, is that patients needing allergy shots will have the option to go to any WellNow Urgent Care center across Western New York, on a day and at a time that first their schedule."

During the initial visit and consultation, allergy patients will meet with Dr. Lomas to complete a skin test, sometimes known as a scratch test, to identify what environmental allergies they may have.

Based on the results of their allergy test, patients will receive and review a personalized, comprehensive treatment plan. At this time WellNow tests for and treats seasonal and environmental allergies, including common indoor and outdoor allergens such as tree and grass pollens, mold, dust and pets.

Following the initial consultation and first allergy shots, patients can select the times andWellNow locationsthat are most convenient for them to continue their immunotherapy.

For more information about WellNow Allergy, including locations, hours of operation and insurances accepted, visitWellNow.com/Allergy.

*PCR -- polymerase chain reaction

See original here:
WellNow Allergy is launched to bring ease and flexibility to testing and immunotherapy, can follow up in Batavia - The Batavian

iShares Trust – iShares Genomics Immunology and Healthcare ETF (IDNA) falls -1.0280% for July 02 – Equities.com

Last Price$ Last TradeChange$ Change Percent %Open$ Prev Close$ High$ low$ 52 Week High$ 52 Week Low$ Market CapPE RatioVolumeExchange

IDNA - Market Data & News

iShares Trust - iShares Genomics Immunology and Healthcare ETF (NYSE: IDNA) shares fell -1.0280% to end trading Friday at $52.01 per share - a net change of $-0.54. Shares traded between $52.55 and $51.61 throughout the day.

Visit iShares Trust - iShares Genomics Immunology and Healthcare ETFs profile for more information.

The New York Stock Exchange is the worlds largest stock exchange by market value at over $26 trillion. It is also the leader for initial public offerings, with $82 billion raised in 2020, including six of the seven largest technology deals. 63% of SPAC proceeds in 2020 were raised on the NYSE, including the six largest transactions.

To get more information on iShares Trust - iShares Genomics Immunology and Healthcare ETF and to follow the companys latest updates, you can visit the companys profile page here: iShares Trust - iShares Genomics Immunology and Healthcare ETFs Profile. For more news on the financial markets be sure to visit Equities News. Also, dont forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE:The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Read more:
iShares Trust - iShares Genomics Immunology and Healthcare ETF (IDNA) falls -1.0280% for July 02 - Equities.com

Moderna and Pfizer vaccines prime T cells to fight variants – Researchers at La Jolla Institute for Immunology (LJI) have found that T cells from…

Researchers at La Jolla Institute for Immunology (LJI) have found that T cells from people who have recovered from COVID-19 or received the Moderna or Pfizer-BioNTech vaccines are still able to recognize several concerning SARS-CoV-2 variants.

Their new study, published online on July 1 in Cell Reports Medicine, shows that both CD4+ helper T cells and CD8+ killer T cells can still recognize mutated forms of the virus. This reactivity is key to the bodys complex immune response to the virus, which allows the body to kill infected cells and stop severe infections.

This study suggests that the impact of mutations found in the variants of concern is limited, says LJI Professor Alessandro Sette, Dr.Bio.Sci., study senior author and member of the LJI Center for Infectious Disease and Vaccine Research. We can presume that T cells would still be available as a line of defense against viral infection.

The researchers emphasize that the study only addresses how the bodys T cells respond to Variants of Concern (VOCs). The researchers emphasize that several of these variants, are linked to lower levels of virus-fighting antibodies.

The current study includes data on four of the most prevalent VOCs. Ongoing studies have been expanded to a larger panel of variants, including the Delta (B.1.617.2) variant, which became prevalent after this study had been initiated. The team has also established relationships with more than 20 different laboratories around the world to help monitor T cell reactivity to VOCs.

These variants are still a concern, but our study shows that even if there is a decrease in antibodies, as other studies have shown, the T cells remain largely unaffected, says LJI Instructor Alba Grifoni, Ph.D. The vaccines still work.

The Johnson & Johnson/Janssen COVID-19 vaccine was not part of this study because it was not available at the time the study was launched.

LJI findings guide COVID-19 vaccine efforts

This study was previously published online as a pre-print in March. The findings were then highlighted by National Institutes of Allergy and Infectious Diseases Director Anthony Fauci, M.D., in a March 31 White House press briefing.

Were learning more and more that these CD4+ and CD8+ T cells are very important in that they cross-react against certain viral variants, Fauci said.

In the time since the paper was first published, the researchers nearly tripled their patient cohort and performed an additional method of stringent statistical analysis. Weve also added an unexposed donor cohort, says study first author Alison Tarke, a Ph.D. student of the University of Genoa, guested in the Sette Lab at LJI.

For the new study, the researchers analyzed T cells from three different groups: people who had recovered from COVID-19, people who had received either the Moderna or Pfizer-BioNTech vaccines, and people never exposed to SARS-CoV-2 (from samples taken before the pandemic).

Both the recovered subjects and the vaccinated subjects were likely to have T cells that recognized the ancestral lineage of SARS-CoV-2. This was the original strain that emerged at the beginning of the pandemic; however, the virus has mutated since December 2019, and several variants have been identified as VOCs.

The question was whether people with T cells trained to recognize the ancestral strain would also recognize the new variants. The researchers tested T cell responses from the donor groups against four prominent VOCs: Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1) and Epsilon (B.1.427/B.1.429).

The researchers found that both vaccinated individuals and the recovered patients had cross-reactive T cells that could target these variants. That is good news for anyone who has received one of the two mRNA vaccines and for anyone who has recovered from any variant of the virus.

With this study, the underlying message is optimistic, adds Tarke. At least, as far as the T cell response goes, your immune system is still able to recognize these new variants and your T cells will be able to respond.

Similar results reporting largely unaffected T cell reactivity has now been presented through independent studies published in Nature and Science Immunology.

Study co-author and LJI Professor Shane Crotty, Ph.D., says this research highlights the importance of enlisting T cells in fighting SARS-CoV-2.

COVID vaccines do a fantastic job of making antibodies that stop SARS-CoV-2 infections, but some of the vaccines do less well at stopping infections from variants, Crotty says. You can think of T cells as a backup system: if the virus gets past the antibodiesif you have vaccine T cells the T cells can probably still stop the variant coronavirus infection before you get pneumonia.

Researchers are now looking for ways to take advantage of how flexible the T cells response appears to be. With T cells already working hard to recognize SARS-CoV-2 variants, Grifoni says future booster shots could increase immunity by prompting the body to produce more antibodies against the variants and/or by adding additional parts of the virus recognized by T cells.

T cell epitopes are well conserved among SARS-CoV-2 variants, so incorporating T cell targets into future COVID vaccines could be a clever way to make sure future variants cant escape the vaccines, adds Crotty.

There is also the possibility that current SARS-CoV-2 research may one day lead to a universal, pan-coronavirus vaccine. This kind of vaccine would train the body to recognize the structural details, such as elements of the spike protein, that all coronaviruses have in common.

This research shows that a pan-coronavirus vaccine is feasible, says Grifoni.

The group is now studying a much larger group of 12 different Variants of Concern (VOCs) and Variants of Interest (VOIs), including the Delta variant (B.1.617.2), Eta (B.1.525), Iota (B.1.526), Kappa (B.1.617.1), Lambda (C37) and the variants B.1.526.1, B.1.617.3, R1 and B.1.1.519.

Sette says hed also like to study T cells from people who have been infected with the variants and see how those T cells react to the ancestral strain of the virus.

The study, Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals was supported by The National Institutes of Health's National Institute of Allergy and Infectious Diseases (AI142742, 75N9301900065, 75N93019C00001 and SARS-CoV-2 Assessment of Viral Evolution program (SAVE) ), the National Institutes of Health (grants U01 CA260541-01, AI036214), UC San Diego T32s (AI007036, AI007384), the Jonathan and Mary Tu Foundation, and a Clinical and Experimental Immunology Course at the University of Genoa, Italy.

Additional study authors include John Sidney, Nils Methot, Esther Dawen Yu, Yun Zhang, Jennifer M. Dan, Paul Rubiro, Aaron Sutherland, Eric Wang, Ricardo da Silva Antunes, April Frazier, Sydney I. Ramirez, Bjoern Peters, Richard Scheuermann, Stephen A. Rawlings, Davey M. Smith and Daniela Weiskopf.

See more here:
Moderna and Pfizer vaccines prime T cells to fight variants - Researchers at La Jolla Institute for Immunology (LJI) have found that T cells from...

Immune system mutiny: mast cells and the mystery of long COVID – Salon

A year before the pandemic, I was diagnosed with a condition called mast cell activation syndrome (MCAS). A hallmark of the syndrome is hypersensitivities in more than one organ system: Food and other triggers can give me abdominal pain and severe diarrhea; my nose swells and I sneeze and wheeze. That sounds like allergies, but I've never tested positive on an allergy test.

Mast cells are among the immune system's first line of defense. They are abundant in the parts of the body that have close contact with the outside world, including the skin, airways, and intestines. Mast cells gone wrong cause allergic symptoms, secreting histamine and giving us itchy eyes, hives, and rashes. Less well understood is their role in modulating the responses of other immune cells. Before the pandemic, researchers had suggested that mast cell dysfunction could explain severe cases of the flu and highlighted the cells' role in shutting down inflammation in a variety of situations. In my case, probably because of a genetic peculiarity, my mast cells overreact.

I was fairly stable on my medication, and then I became sick with Covid-19. Months after the virus had passed and I no longer had pneumonia, I was still fighting fatigue and breathlessness. My symptoms also flared up erratically. On some mornings, for example, the oatmeal I had relied on for years could cause me abdominal pain. "Once the mast cell response is turned up, it doesn't wind down just because the infection is gone," explained my doctor, Leo Galland, a New York internist who specializes in difficult cases.

MCAS often seems to first emerge after a virus. Could it explain any of the symptoms of the growing group of patients with long Covid? Congress has now dedicated more than a billion dollars towards research into why so many post-Covid patients roughly a quarter, more often women still feel ill long after their infection. In Facebook groups and elsewhere, people with plausible symptoms for instance, severe lingering rashes and months of hives have been trading information about remedies for the disease. Severe fatigue after exercise suggested myalgic encephalomyelitis/chronic fatigue syndrome, which some say is linked to MCAS. Others became lightheaded when they stood up, which might mean they had postural orthostatic tachycardia syndrome (POTS). Spend an hour searching online, and you'll find papers saying POTS, too, may be a manifestation of MCAS.

But getting a workup for the syndrome can be a long ordeal. The full range of tests and treatments aren't routinely covered by insurance, leaving some patients to pay thousands of dollars out of pocket. Before you get there, you need to find a sympathetic doctor: Researchers don't agree on whether the illness is rare, or quite common.

I was lucky; Galland took me on in the 1980s. Long before the microbiome became a news item, he diagnosed me with intestinal dysbiosis a disturbed gut. We don't know why I got sick when I did, but when I showed up in Galland's office, I was a young woman on an absurdly limited diet with a myriad of fluctuating symptoms. On a trip to Tucson, as just one example, my face and arms ballooned, and then shrank on the plane home. I had been exposed to a fungus in the desert. My grandmother commiserated; when her face swelled up, her doctors in Antwerp, in the 1930s, pulled out all of her teeth. She had no explanation.

Interestingly, disturbances in the gut may be linked to severe Covid-19, and correcting them a possible path to health for long Covid sufferers. Mast cells may have a unique role in communicating with gut bacteria. In midlife, I fit the profile for irritable bowel syndrome (IBS), the abdominal pain, often accompanied by diarrhea or constipation, that afflicts as much as 20 percent of the population, and often sets in after a virus. Desperate, in 2018, I had just completed a trial of hypnotherapy for IBS when my digestion took an embarrassing turn, with accidents in taxis, and I could no longer eat outside my home.

A new dietician, Tamara Duker Freuman, author of "The Bloated Belly Whisperer," helped me identify the worst offenders: foods that are high in histamine, which can be found in everything from alcohol to avocados. After further testing, Galland put me on a regime: an arsenal of mast cell modulators and anti-histamines, including Pepcid, which also blocks histamine.

And I got better.

* * *

Mast cells were first named in 1878 by a German-Jewish Nobel Prize winner, Paul Ehrlich, a father of modern immunology who is most famous for discovering the cure for syphilis. At the turn of the century, scientists discovered anaphylaxis, the classic mast cell allergic reaction. The word comes from the Greek ana (against) and phylaxis (protection). The idea that an immune response could actually hurt us, rather than protect us, came as shock. Current research about the gut and immunity may change the paradigm again.

Five decades later, in 1949, scientists described a rare genetic disorder called mastocytosis, in which mast cells produce clones, building up in the skin, bones, and other organs. It wasn't until the 1980s that researchers began to notice that mast cells could become hyper-responsive or over-activated without cloning.

On a separate track, since the 1990s, researchers have explored mast cell activity in IBS. (A clinical trial of Pepcid and Zyrtec for difficult IBS cases is currently underway at the University of Cincinnati.) Kyle Staller, director of the Gastrointestinal Motility Laboratory at Massachusetts General Hospital, now sometimes prescribes Pepcid if he sees other signs like hives, to patients who ask him to consider a histamine or MCAS issue. "I think anyone who's been following the science closely has to start wondering, 'How much could this be playing a role in that IBS patient who's in front of us on a given day?'" he told me.

Competing proposals for diagnostic criteria emerged after 2010. Both proposals say that doctors should rule out other explanations for a person's symptoms, and that symptoms should appear in a least two organ systems (in my case, it affects my gut, nose, and skin). Both proposals require lab tests but they disagree on which tests are necessary, and on the ranges that would indicate someone has MCAS, as well as other details. Because lab results are elusive, Galland and some other doctors rely on a medical history instead.

The disagreement has led to two camps. In camp one, the condition is rare; in camp two, it occurs in up to 17 percent of the adult population. Specialists in camp one say patients are misled: "More and more patients are informed that they may have [mast cell activation syndrome] without completing a thorough medical evaluation," an international group of 24 authors, led by Peter Valent, a hematologist and stem cell researcher at the Medical University of Vienna, wrote in April 2019 in the Journal of Allergy and Clinical Immunology.

A year later, a largely American group of 43 authors led by Lawrence Afrin, one of the earliest mast cell activation researchers, countered in the journal Diagnosis that patients are suffering and even dying from underdiagnosis. By then the pandemic had arrived, and Afrin suggested that some patients with long Covid might be experiencing MCAS.

Patients were seeing links as well. For example, the distinct POTS symptom of extreme lightheadedness, once often dismissed as a problem of anxious young women, emerged as one of the odder long Covid symptoms. POTS, which has been reported by patients who experienced Lyme and other infections, may involve histamine and several other chemicals released by mast cells. It is known to overlap with MCAS.

Last fall, when the Centers for Disease Control and Prevention reported on what it labeled multisystem inflammatory syndrome (MIS), the name rang bells: MCAS is clearly a multi-system inflammatory syndrome. Theoharis Theoharides, a professor of immunology at Tufts University who has studied mast cells for more than 40 years, wrote that MIS patients should be evaluated for MCAS.

Mariana Castells, director of the Mastocytosis Center at Brigham and Women's Hospital in Boston, told me in an email that she's seen no data showing that long Covid patients have the requisite diagnostic markers of MCAS.

Observers agree that the long Covid group probably includes people with different vulnerabilities. It would be marvelous indeed, if, one day, we found a single powerful concept to understand post-viral illness.

In the meantime, you might not need to fit either group's criteria for MCAS, a difficult and chronic illness, to experience your mast cells' betraying you sometimes. "Like many, many conditions, over time we [may] learn that there's a spectrum of disease," Staller said. "It's not an all or nothing phenomenon."

Even the group that sees MCAS as rare acknowledges the existence of a less severe form of mast cell activation that does not meet MCAS criteria. Theoharides has detailed several categories of the illness. He told me that he'd guess half of patients diagnosed with IBS might have mast cell activation of some kind.

If mast cell dysfunction is truly common, I trust the online buzz to help us find out. Crowdsourcing on patient forums is here to stay. And it's good, after all, that sick people shared information, found support, and made long Covid a "thing" with ontological status.

Growing up, I had wondered if my grandmother's multiple "allergies" were real. We didn't laugh, but we didn't exactly believe her. Then it happened to me.

* * *

Temma Ehrenfeld is a writer and ghostwriter in New York drawn to philosophy and psychiatry. Her most recent book is "Morgan: The Wizard of Kew Gardens."

This article was originally published on Undark. Read the original article.

Original post:
Immune system mutiny: mast cells and the mystery of long COVID - Salon

AbbVie: Is the Price Right for Long-Term Investment? – The Motley Fool

As Foolish investors, we're seeking long-term success. That means paying attention not just to a company's operating fundamentals, but to how the market is valuing that company.

Imagine two investors, Anne and Barry. Both of them are interested in buying shares of a coffee company -- we'll call it Starfrancs. Both of them have researched Starfrancs's balance sheet and fundamentals, and they think it's a solid business. Starfrancs is fairly valued at $100, but Anne, who's paying less attention to valuation, buys her shares at $120. Meanwhile, Barry is able to buy them on a dip at just $80 each.

Image Source: Getty Images.

Even though both investors own the same company, Barry positioned himself with a much greater margin of safety in the event that the business doesn't perform as well as expected in the future. Buying the stock at a discount makes it more likely that Barry will benefit from capital appreciation in the stock price as Starfrancs reverts to its fair value.

So we can see it's important to consider fair value when determining whether a stock is worth buying. Let's take a look at pharma giant AbbVie (NYSE:ABBV), which is up 18% over the past year. Has this share price increase taken it past fair value?

In an effort to determine the fair value of AbbVie's shares, we will be using the discounted cash flow, or DCF, model.

The DCF model lets you estimate what a company is worth by estimating the sum of its future cash flows based on the previous year of cash flows. If the results are lower than the current share price, the company is likely not worth further consideration. However, results that are higher than the current share price imply a potentially enticing investment.

Here's the formula:

As fellow Fool Matthew Frankel writes in the linked article above, "That large symbol at the front of the formula is the Greek letter sigma, and it is used to denote the sum of several quantities. In other words, this symbol tells you to perform a present value calculation for each year's cash flow and then add them all together."

The first input into the DCF model is trailing-12-month (TTM) cash flow per share, though TTM earnings per share (EPS) can also be used. In AbbVie's case, these numbers are about the same. We'll opt to use AbbVie's TTM EPS, which is $11.09.

AbbVie's business is solid -- more on that below -- but as investors, we always want to leave ourselves with a margin of safety in case a company fails to meet our expectations. For that reason, we'll assume earnings growth will be 3% annually over the next five years -- well below the analyst consensus of 4.5%. What's more, while it is likely that AbbVie will deliver some level of earnings growth after that, we'll assume zero growth after five years.

Finally, we're using 10% -- the S&P's average annual return over the long term -- as our discount rate or required annual total return rate as a benchmark to adequately reward us for our efforts as investors.

We arrive at a fair value for shares of AbbVie of $125.55 a share, which is moderately higher than its current share price of $112.55. From this, we can conclude that AbbVie is undervalued.

Now that we know its fair value, let's talk about AbbVie's business. Its immunosuppressant Humira was the world's best-selling drug in 2019, and some investors have worried about what will happen when the drug goes off-patent in the U.S. in 2023. But the company has a number of paths, specifically within the oncology and immunology fields in which it is a leader, to stabilize its revenues and earnings.

Oncology and immunology are already the largest segments of the pharma industry by annual spending, and both are poised to benefit from 9% to 12% compound annual growth rates through 2025 (for other areas, that number is 5%). That should bring annual spending in each field to $273 billion and $175 billion, respectively, per FiercePharma.

AbbVie's oncology and immunology segments (which include Humira) comprised about 57% of the company's Q1 2021 revenue. That means the bulk of the company's sales are generated in the two most dominant, fastest-growing areas of pharma. And AbbVie is in a position to offset any near-term declines in Humira revenue with its two other immunology blockbusters, Skyrizi and Rinvoq, which combined saw year-over-year growth in excess of 100% to a combined $900 million in Q1 2021 -- further supporting the notion of massive demand in the immunology field of pharma. Further, AbbVie's two oncology drugs, Imbruvica and Venclexta, saw sales climb 7.3% year over year to a combined $1.7 billion in Q1 2021.

AbbVie is an industry leader in the rapidly growing oncology and immunology fields. It has a solid dividend of about 4.6% and is well positioned to guard against any loss of revenue from Humira. Its current price of about $113 looks like a moderate discount to fair value, making this company worthy of attention from investors looking to start or add to a position, anywhere below $125 a share.

This article represents the opinion of the writer, who may disagree with the official recommendation position of a Motley Fool premium advisory service. Were motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Go here to read the rest:
AbbVie: Is the Price Right for Long-Term Investment? - The Motley Fool

Microbiome Medicine: Scientists Harness the Body’s ‘Bugs’ to Treat Asthma, MS, and More – UCSF News Services

Plenty of probiotic yogurts, pickles, and kombuchas claim to boost our digestive health with armies of microbes, but some scientists have more ambitious therapeutic plans for the bugs that colonize us. They hope to leverage these microbes as living therapeuticsfor a range of health conditions, including ulcerative colitis, multiple sclerosis, eczema, and asthma.

Remove this text and use the embed button to add an image.

UCSF launched a Living Therapeutics Initiative to accelerate the development and delivery of revolutionary treatments.

Learn More

Our guts, skin, and other regions of the body harbor trillions of microbes, as many as we have cells of our own. Each of these microbes bacteria, viruses, microscopic fungi, and others that make up the human microbiome brings with it a unique genome.

The composition of our microbiome and its microbial pan-genome is shaped by diet and environment, which in turn affect its important influences on human physiology, from digestion to brain health to immune function.

One real advantage of the microbiome is that its a dynamic system, said Susan Lynch, PhD, professor of gastroenterology and director of the UCSF Benioff Center for Microbiome Medicine. What were thinking about is how we can leverage microbes in engineering that system to improve health or prevent disease.

Much of the clinical research on the microbiome revolves around its connection with autoimmune disorders, such as rheumatoid arthritis, Crohns disease, and multiple sclerosis (MS), which altogether affect 24 million Americans. While genetics factor into why some people develop autoimmune disorders, environmental triggers likely contribute, said Sergio Baranzini, PhD, a neurology professor at the UCSF Weill Institute for Neurosciences, who studies the genetics and immunology of MS.

This is where we turn to the microbiome, he said. Because it is so influenced by food and other environmental factors, its a proxy for the environment.

A decade ago, when rapid DNA sequencing techniques made it cost-effective to identify bacteria, Baranzini began studying the relationship between the gut microbiome and MS, an autoimmune disorder in which the immune system attacks the nervous system. He had been intrigued by reports of other autoimmune conditions in which patients and controls were found to have different gut microbes.

In fact, most of our immune cells reside in our gut, and they depend on short-chain fatty acids produced when gut bacteria digest dietary fiber.

Baranzini compared stool and blood samples from people with MS to those from a member of the same household without MS. He found that the two populations of gut bacteria indeed differed, and that the blood from the person with MS had considerably fewer regulatory T cells, which normally tamp down the bodys immune response.

The deficiency of these T cells, Baranzini hypothesizes, is likely tied to the microbiome and impairs the bodys ability to control inflammation. He launched the International MS Microbiome Study to seek a comprehensive picture of gut microbiota in people with MS.

B cells (green), dendritic cells (blue) and T cells (red) are immune cells that help maintain the delicate relationship between the gut microbiome and the host. Image byLauren Rodda

Weve started discovering how diverse our microbiota are and how intimately they are in contact with our own immune systems, he said. And we now know that theres a lot of back-and-forth between the immune system and cells in the intestine that were only beginning to understand.

Microbial therapies for autoimmune disorders already exist in the form of fecal microbial transplants, or FMT, which involves taking stool samples from healthy individuals, isolating the gut microbes, and giving them to patients via a pill or enema.

This past April, Najwa El-Nachef, MD, an associate professor of medicine, wrapped up a clinical trial for ulcerative colitis and found that some patients respond much better to FMT than others, with a few reporting improvements in inflammatory skin and joint conditions as well. Her next step is to identify the best patients for microbiota-based therapy and to develop more targeted treatments.

For a subset of ulcerative colitis patients, manipulating the microbiome may provide a way to treat their autoimmune disease without suppressing their immune system, she said.

Our microbiome begins to take shape early, so interventions at the start of life can set the stage for future health. Lynch has focused some of her research on the gut microbiota during a babys first months of development. Its a critical time when the composition of the babys microbiome, influenced by the mother and the environment, can affect the development of the immune system and immune memory, with lasting consequences.

Susan Lynch, PhD, is the director of the UCSF Benioff Center for Microbiome Medicine. Photo by Barbara Ries

Najwa El-Nachef, MD, is studying the role of the microbiome in treatingulcerative colitis. Photo by Barbara Ries

Weve found that the gut microbiome at one month of age really predicts the risk of developing asthma and airway disease later in childhood, she said. Lynch and her team have identified specific microbial products that drive the dysfunction of regulatory T cells, which is associated with subsequent disease.

Weve considered that engineering the gut microbiome during this key window of immune training could have a long-term beneficial impact on the health status of high-risk children, she said

Lynch has developed a live microbial intervention administered at birth to babies at high-risk for asthma, comprised of bacteria that can modulate immune response. Their bacterial genomes encode a range of functions consistently absent from high-risk infant gut microbiomes.

The idea is to shape the developing gut microbiome by providing bacteria that can train the immune system early in life with their microbial products and metabolites, ultimately influencing the microbiomes function in the long term.

Our skin harbors its own set of microbes that interact with immune cells and protect the skin from infection.

Clinical trials using skin microbiota are already showing promise for patients with eczema, an autoimmune condition that can flare up when staph bacteria proliferate, said Tiffany Scharschmidt, MD, an associate professor of dermatology. The trials involve supplementing the bacteria that ordinarily keep the staph population under control.

Tiffany Scharschmidt, MD, is studying using skin microbiota arefor patients with eczema.Photo by Barbara Ries

Sergio Baranzini, PhD, is studying he genetics and immunology of multiple sclerosis.Photo bySteve Babuljak

As we gain more understanding of the interaction between the skin microbiome and its immune system, well see other microbial-based treatments emerging, she said. In the future, therapeutic skin microbes could even be genetically engineered to produce needed compounds.

The gut microbiome is, of course, intimately tied with digestion, producing diet-derived compounds that program immune cells and produce nutrients critical for the growth of the cells that line our intestines. The basic digestive and immune functions in our gut depend on colonization by specific bacteria, said Peter Turnbaugh, PhD, an associate professor of microbiology and immunology. Our intestinal cells have evolved receptors just lying in wait to sense the chemicals produced by the gut microbiome.

Turnbaugh has found that our inner critters also play a role in metabolizing medication. A better understanding of that role, he said, could increase drug efficacy.

We think the microbiome might be second only to the liver in determining how drugs are metabolized in the body, affecting how a patient responds to an existing therapy, he said.

Some antibiotics, for example, are activated by enzymes produced by the gut microbiota. Our microbial tenants may even influence how substances move around the body or change a drugs mechanism of action, but much remains unexplored in this area, said Turnbaugh.

Deeper knowledge of how our gut microbiome interacts with drugs might enable physicians to prescribe treatments that align with or supplement our individual microbiome, a new form of precision medicine.

Lynch believes that the therapeutic advances we can make through understanding the microbiome will rival those that came with understanding the human genome, particularly on autoimmune disorders.

Though the human microbiome field is still relatively young, it has already provided exceptional insights into the dependence of human physiology on our dynamic microbial inhabitants and offers a new set of tools to elicit better health, said Lynch. Translating these early observations into new live biotherapeutics represents the next step in realizing the potential of this field.

Read the rest here:
Microbiome Medicine: Scientists Harness the Body's 'Bugs' to Treat Asthma, MS, and More - UCSF News Services

Novartis says it overpaid Roche’s Genentech nearly $210M in a licensing dealand it wants its money back – FiercePharma

For years, Novartis said it dutifully shelled out tens of millions to Genentech as part of a patent licensing deal that dated back to 2005. Later, the Swiss pharma discovered it accidentally overpaid by nearly $210 million.

Those are the central arguments in a lawsuit filed by Novartis against its Swiss pharma counterpart seeking $209.5 million.In the suit, whichrecently made its way to California federal court, Novartis says Genentech isn't coughing up the dough.

Novartis claims Genentech was aware, or at least shouldve known, that the company was overpaying the entire time.

The paymentsstemmed from a 2005 licensing agreement Genentech struck with then Chiron Corporation related to its antibody patents. Novartis picked up Chiron a year later and developed several commercial antibody products from the pact, notablyimmunology meds Ilaris and Cosentyx, the suit says.

RELATED:Novartis hits setback in bid to block Regeneron's Eylea prefilled syringe as dual lawsuits drag on

Instead of alerting Novartis of the overpayments, Genentech continued to seek, accept, and retain the funds driven by Ilaris and Cosentyx sales, even though they werent entitled to them, Novartis argued in the filing.

While terms of the initial licensing deal weren't disclosed, Novartis maintains itperformed all or substantially all of its obligations under the deal and later learned of the overpayments after it expired.

Meanwhile, lawyers representing Genentech dismissed Novartis claims in a filing seeking to move the case from state to federal court, arguing the claims fall under federal patent law.

The companies werent immediately available for comment.

RELATED:Novartis' closely watched canakinumab hits a snag in lung cancer. What's next for the anti-inflammatory drug?

Cosentyx, which first launched in 2015, directly inhibits interleukin-17A (IL-17A), an important cytokine involved in the inflammation of psoriatic arthritis, moderate to severe plaque psoriasis, ankylosing spondylitis and non-radiographic axial spondyloarthritis.

The treatment has become Novartis largest brand, driving $3.9 billion in sales last year, up 13% compared with the year prior.

Meanwhile, sales of IL-1beta inhibitor Ilaris came in at roughly $873 million, up 30%. Despite efforts to push the medicine, also known ascanakinumab,into fields outside immunology, Novartis has run intomultiple setbacks, including in heart disease, COVID-19 and, most recently, non-small cell lung cancer.

Read the original here:
Novartis says it overpaid Roche's Genentech nearly $210M in a licensing dealand it wants its money back - FiercePharma

Cue Biopharma to Present at the 2021 Federation of Clinical Immunology Societies (FOCIS) Virtual Annual Meeting – Yahoo Finance

CAMBRIDGE, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patients body, announced today it will give a presentation at the 2021 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting, which is being held virtually from June 8-11, 2021.

Anish Suri, president and chief scientific officer of Cue Biopharma, will discuss preclinical data on CUE-401, the Companys most recent autoimmune drug product candidate. CUE-401, part of the CUE-400 series designed for differentiation and expansion of induced regulatory T cells (iTregs), is a bispecific molecule engineered to deliver the two signals, transforming growth factor beta (TGF-) and interleukin 2 (IL-2), required to induce iTregs in vivo.

Presentation DetailsSession Title: CUE-401: A Novel IL-2/TGF-beta Fusion Protein for the Induction of CD4+ FOXP3+ Regulatory T cellsPresenter: Anish Suri, Ph.D., president and chief scientific officer of Cue BiopharmaSession: Late Breaking Abstracts (Part II)Date and Time: Thursday, June 10, 2021 from 3:45 p.m. 4:00 p.m. PDT

The recorded presentation and poster will be available in the Investor & Media section of the Companys website under Scientific Publications and Presentations, following the presentation at FOCIS 2021 annual meeting.

Presentation data highlights include:

In vivo data show that CUE-401 can effectively induce FOXP3-expressing iTregs from T cells obtained from healthy donors as well as patients suffering from rheumatoid arthritis and inflammatory bowel diseases.

CUE-401 induced iTregs suppressed effector T cell responses.

A single dose of CUE-401 was shown effective at inducing Tregs in mice with active and ongoing autoimmunity.

Dr. Suri commented, We are very excited to share these promising preclinical data demonstrating CUE-401 has the ability to induce and expand regulatory T cells in vitro and in vivo. We believe this is an innovative and potentially effective means of suppressing chronic inflammatory diseases and may provide a more meaningful and lasting benefit to patients suffering from numerous autoimmune diseases, graft versus host disease (GVHD) and even transplant rejection.

About FOCIS Annual Meeting The Federation of Clinical Immunology Societies is a key forum where opinion leaders come together to chart the path to the next major breakthrough in disease therapy. Through FOCIS, researchers and clinicians share knowledge across traditional disease borders, and identify commonalities between treatments and therapies that are life-changing for those impacted by immune-mediated diseases. The FOCIS Annual Meeting educates clinicians, researchers and trainees in the broad discipline of clinical immunology. FOCIS is the worlds leader in immunology education and in training future generations of clinical immunologists. Initially established as a cross-disciplinary meeting, FOCIS held its first Annual Meeting in 2001. After two successful consecutive meetings, FOCIS was incorporated as a 501(c)3 organization in 2003. Today, FOCIS has 58 Member Societies, representing roughly 65,000 clinician scientists.

About Cue BiopharmaCue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patients body to transform the treatment of cancer, infectious disease and autoimmune disease. The companys proprietary Immuno-STAT (Selective Targeting and Alteration of T cells) platform, is designed to harness the bodys intrinsic immune system without the need for ex vivo manipulation.Headquartered in Cambridge, Massachusetts, the company is led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.

Story continues

For more information, visit https://www.cuebiopharma.com and follow us on Twitter at https://twitter.com/CueBiopharma.

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the safe harbor created by those sections. Such forward-looking statements include, but are not limited to, those regarding: the companys estimate of the period in which it expects to have cash to fund its operations; the companys belief that the Immuno-STAT platform stimulates targeted immune modulation through the selective engagement of disease-relevant T cells; and the companys business strategies, plans and prospects. Forward-looking statements, which are based on certain assumptions and describe the companys future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as believe, expect, may, will, should, would, could, seek, intend, plan, goal, project, estimate, anticipate, strategy, future, likely or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the companys strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the companys actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the companys limited operating history, limited cash and a history of losses; the companys ability to achieve profitability; potential setbacks in the companys research and development efforts including negative or inconclusive results from its preclinical studies, its ability to secure required U.S. Food and Drug Administration (FDA) or other governmental approvals for its product candidates and the breadth of any approved indication; adverse effects caused by public health pandemics, including COVID-19, including possible effects on the companys trials; negative or inconclusive results from the companys clinical trials or preclinical studies or serious and unexpected drug-related side effects or other safety issues experienced by participants in clinical trials; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to the FDA; the companys reliance on licensors, collaborators, contract research organizations, suppliers and other business partners; the companys ability to obtain adequate financing to fund its business operations in the future; operations and clinical the companys ability to maintain and enforce necessary patent and other intellectual property protection; competitive factors; general economic and market conditions and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of the companys most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by the company in this press release is based only on information currently available to the company and speaks only as of the date on which it is made. The company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor ContactGeorge B. Zavoico, Ph.D.VP, Investor Relations & Corporate Development Cue Biopharma, Inc. gzavoico@cuebio.com

Media ContactDarren Opland, Ph.D.LifeSci Communicationsdarren@lifescicomms.com

Originally posted here:
Cue Biopharma to Present at the 2021 Federation of Clinical Immunology Societies (FOCIS) Virtual Annual Meeting - Yahoo Finance